$0.11
24.41% yesterday
Nasdaq, Jun 13, 10:16 pm CET
ISIN
US67022C1062
Symbol
NCNA
Sector
Industry

NuCana plc Sponsored ADR Stock price

$0.11
+0.08 249.24% 1M
-1.16 90.95% 6M
-1.08 90.34% YTD
-2.92 96.21% 1Y
-147.89 99.92% 5Y
-403.64 99.97% 10Y
-403.64 99.97% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.04 24.41%
ISIN
US67022C1062
Symbol
NCNA
Sector
Industry

Key metrics

Market capitalization $920.00k
Enterprise Value $-7.98m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.30
P/B ratio (TTM) P/B ratio 2.02
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-31.21m
Free Cash Flow (TTM) Free Cash Flow $-26.33m
Cash position $9.16m
EPS (TTM) EPS $-0.20
Short interest 0.40%
Show more

Is NuCana plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

NuCana plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast NuCana plc Sponsored ADR:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast NuCana plc Sponsored ADR:

Hold
100%

Financial data from NuCana plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.77 6.77
18% 18%
-
- Research and Development Expense 24 24
28% 28%
-
-31 -31
26% 26%
-
- Depreciation and Amortization 0.71 0.71
9% 9%
-
EBIT (Operating Income) EBIT -31 -31
26% 26%
-
Net Profit -26 -26
31% 31%
-

In millions USD.

Don't miss a Thing! We will send you all news about NuCana plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NuCana plc Sponsored ADR Stock News

Neutral
GlobeNewsWire
12 days ago
Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma
Neutral
GlobeNewsWire
3 months ago
Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025
Neutral
Business Wire
4 months ago
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). “We are delighted to welcome Don to our executive team,” said Gr...

Company Profile

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh S. Griffith and Christopher B. Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

Head office United Kingdom
CEO Hugh Griffith
Employees 21
Founded 1997
Website www.nucana.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today